Theravance Biopharma (TBPH) AI Stock Analysis

• Market Cap: $694.99M
• Dividend Yield: N/A
• Average Volume (3M): 351.86K
• Price to Earnings (P/E): 59.0
• Beta (1Y): 0.98
• Revenue Growth: 24.49%
• EPS Growth: N/A
• Country: US
• Employees: 97
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): 1.08
• Shares Outstanding: 50,361,298
• 10 Day Avg. Volume: 612,637
• 30 Day Avg. Volume: 351,862
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.38
• Enterprise Value/Revenue: 3.46
• Enterprise Value/Gross Profit: 3.46
• Enterprise Value/Ebitda: 5.80
• 1Y Price Target: $17.83
• Price Target Upside: 29.20% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6

• Rating: 66 Neutral
• Price Target: $15.00 ▲(8.70% Upside)

Theravance Biopharma's overall stock score reflects strong technical momentum and positive corporate events, offset by high valuation concerns and ongoing profitability challenges. The company's strategic advancements and cash flow improvements are promising, but financial stability remains a key area for improvement.

Positive Factors

Analyst Recommendation

Analyst recommendation is a 'Buy' for Theravance Biopharma stock with a price target of 24.00.

Clinical Trial Results

The CYPRESS trial is significantly de-risked by preceding Phase 3 results where ampreloxetine showed positive trends without worsening of supine hypertension.

Market Need

A large majority of MSA patients with neurogenic orthostatic hypotension require pharmacologic treatment, indicating a strong market need.

Negative Factors

Current Treatment Limitations

Currently available treatment options are inadequate for up to 70% of patients, highlighting a gap in effective solutions.

Patient Management Challenges

About 50% of patients develop treatment limiting supine hypertension.

Theravance Biopharma Business Overview & Revenue Model

Company Description

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.

How the Company Makes Money

Theravance Biopharma generates revenue through multiple streams, primarily from the sale of its pharmaceutical products, particularly Vibativ. Additionally, the company earns revenue through collaboration agreements and licensing partnerships with other pharmaceutical companies, which may include upfront payments, milestone payments, and royalties on product sales. The company may also receive funding through grants and research contracts aimed at supporting its drug development initiatives. Significant partnerships with larger pharmaceutical firms can enhance its revenue potential by providing financial resources and broader market access for its products.

Theravance Biopharma Financial Statement Overview

Summary

Theravance Biopharma shows positive revenue and cash flow growth, indicating potential recovery. However, persistent profitability challenges and historical negative cash flows suggest underlying financial instability. The company needs to improve operational efficiency and profitability to enhance its financial health.

Income Statement

Theravance Biopharma shows a positive revenue growth rate of 18.29% TTM, indicating a recovery trend. However, the company struggles with profitability, as evidenced by negative EBIT and net profit margins. The gross profit margin remains strong at 100%, but the negative net profit margin suggests challenges in managing operating expenses.

Balance Sheet

The company's debt-to-equity ratio is relatively low at 0.29 TTM, indicating manageable leverage. However, the negative return on equity highlights ongoing profitability issues. The equity ratio is not provided, but the overall balance sheet suggests moderate financial stability with potential risks due to negative ROE.

Cash Flow

Theravance Biopharma shows a significant improvement in free cash flow growth at 658.17% TTM, reflecting enhanced cash generation capabilities. The operating cash flow to net income ratio is positive, indicating efficient cash flow management. However, historical negative cash flows pose a risk to sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	77.20M	64.38M	57.42M	51.35M	55.31M	71.86M
Gross Profit	77.20M	64.38M	57.42M	44.76M	48.02M	-189.10M
EBITDA	46.09M	-38.45M	-42.66M	-79.86M	-249.39M	-294.00M
Net Income	13.03M	-56.42M	-55.19M	-92.82M	-199.43M	-278.02M
Balance Sheet
Total Assets	426.04M	354.16M	382.00M	607.40M	374.82M	469.06M
Cash, Cash Equivalents and Short-Term Investments	338.80M	88.35M	102.43M	327.48M	173.47M	292.94M
Total Debt	46.46M	49.82M	49.16M	74.12M	652.08M	647.06M
Total Liabilities	201.19M	178.62M	169.00M	165.60M	713.39M	772.81M
Stockholders Equity	224.85M	175.54M	213.00M	441.80M	-338.57M	-303.75M
Cash Flow
Free Cash Flow	244.78M	-11.87M	-29.48M	-187.56M	-211.26M	-257.02M
Operating Cash Flow	245.01M	-11.54M	-27.00M	-186.99M	-207.86M	-250.40M
Investing Cash Flow	-7.34M	12.28M	-32.70M	1.15B	124.49M	10.72M
Financing Cash Flow	-2.09M	-2.50M	-198.93M	-758.81M	91.86M	263.08M

Theravance Biopharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 13.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TBPH, the sentiment is Positive. The current price of 13.8 is above the 20-day moving average (MA) of 12.48, above the 50-day MA of 11.66, and above the 200-day MA of 10.01, indicating a bullish trend. The MACD of 0.72 indicates Negative momentum. The RSI at 76.83 is Negative, neither overbought nor oversold. The STOCH value of 73.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TBPH.

Theravance Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TBPH	66 Neutral	$694.99M	59.00	6.23%	―	24.49%	―
KROS	66 Neutral	$605.58M	49.54	3.33%	―	85820.30%	―
SAGE	54 Neutral		―		―	-27.59%	34.00%
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%
CAPR	43 Neutral	$295.79M	―	-120.15%	―	-50.68%	-76.38%
MGTX	41 Neutral	$603.36M	―	-379.53%	―	366.84%	-35.87%
MNMD	40 Neutral	$760.12M	―	-59.11%	―	―	39.66%

Theravance Biopharma Corporate Events

Theravance Completes Enrollment in Phase 3 CYPRESS Study

On August 25, 2025, Theravance Biopharma announced the completion of enrollment in the open-label portion of its pivotal Phase 3 CYPRESS study for ampreloxetine, targeting symptomatic neurogenic orthostatic hypotension (nOH) due to multiple system atrophy (MSA). This condition affects approximately 80% of MSA patients, leading to severe symptoms like dizziness and fainting. The study aims to address the unmet need for effective nOH treatments, with topline results expected in Q1 2026. If successful, ampreloxetine could become the first therapy to provide durable benefits for the estimated 40,000 U.S. patients with MSA-related nOH, potentially transforming treatment options in this underserved market.

Theravance Biopharma Settles Patent Dispute with Cipla

On August 15, 2025, Theravance Biopharma and Mylan entered into a Settlement Agreement with Cipla to resolve ongoing patent litigation over YUPELRI® inhalation solution. The agreement allows Cipla to manufacture and market a generic version of YUPELRI® in the U.S. starting April 23, 2039, pending review by U.S. authorities, while litigation continues against Mankind Pharma Ltd.

Theravance Biopharma Gains Milestone Payment from Viatris

On June 26, 2025, Theravance Biopharma announced that Viatris secured regulatory approval from China’s NMPA for YUPELRI® (revefenacin) inhalation solution, marking it as the first once-daily nebulized LAMA for COPD maintenance treatment in China. This approval triggers a $7.5 million milestone payment from Viatris to Theravance, expected in Q3 2025, and positions Theravance for further sales-based milestones and royalties, enhancing its financial standing without incurring commercial costs in China.

Theravance Biopharma Settles Patent Litigation with Eugia

On June 5, 2025, Theravance Biopharma and Mylan entered into a Settlement Agreement with Eugia Pharma to resolve ongoing patent litigation concerning the YUPELRI® inhalation solution. The agreement allows Eugia to manufacture and market a generic version of YUPELRI® in the U.S. starting April 23, 2039, pending review by the U.S. Department of Justice and the Federal Trade Commission, while litigation continues against other ANDA filers.

Theravance Biopharma Sells Trelegy Royalty Interest to GSK

On May 30, 2025, Theravance Biopharma entered into an agreement with GlaxoSmithKline (GSK) to sell its remaining royalty interest in Trelegy Ellipta for $225 million. This transaction, part of the company’s strategic efforts to maximize shareholder value, follows a previous sale of Trelegy royalty interests in 2022 for $1.1 billion. The deal underscores Theravance Biopharma’s strategy to monetize its assets while retaining rights to potential milestone payments from Royalty Pharma.